The positively charged COOH-terminal glycosaminoglycan-binding CXCL9(74-103) peptide inhibits CXCL8-induced neutrophil extravasation and monosodium urate crystal-induced gout in mice

Journal of Biological Chemistry

Volumn 290, Issue 35, 2015, Pages 21292-21304

  Vanheule, Vincent ^a   Janssens, Rik ^a   Boff, Daiane ^b   Kitic, Nikola ^c   Berghmans, Nele ^a   Ronsse, Isabelle ^a   Kungl, Andreas J ^c   Amaral, Flavio Almeida ^b   Teixeira, Mauro Martins ^b   Van Damme, Jo ^a   Proost, Paul ^a   Mortier, Anneleen ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE;

ANTI-INFLAMMATORIES; CHEMOTACTIC ACTIVITY; COOH-TERMINAL; GLYCOSAMINOGLYCANS; INTRAVENOUS INJECTIONS; NEUTROPHIL MIGRATION; POSITIVELY CHARGED; URATE CRYSTALS;

PEPTIDES;

ANTIINFLAMMATORY AGENT; CARBOXYLIC ACID; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; CXCL9 PEPTIDE[74-103]; GLYCOSAMINOGLYCAN; INTERLEUKIN 8; UNCLASSIFIED DRUG; URATE; PEPTIDE; URIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL MIGRATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG EFFICACY; GOUT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; MIGRATION INHIBITION; MOLECULAR GENETICS; NEUTROPHIL CHEMOTAXIS;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL MIGRATION INHIBITION; CHEMOKINE CXCL9; CHEMOTAXIS, LEUKOCYTE; GLYCOSAMINOGLYCANS; GOUT; HUMANS; INTERLEUKIN-8; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEUTROPHILS; PEPTIDES; URIC ACID;

EID: 84940772260     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.649855     Document Type: Article

References (72)

1. Rot, A., and von Andrian, U. H. (2004) Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891-928
2. Murphy, P. M., Baggiolini, M., Charo, I. F., Hébert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., and Power, C. A. (2000) International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176
3. Ley, K., Laudanna, C., Cybulsky, M. I., and Nourshargh, S. (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689
4. Handel, T. M., Johnson, Z., Crown, S. E., Lau, E. K., and Proudfoot, A. E. (2005) Regulation of protein function by glycosaminoglycans: as exemplified by chemokines. Annu. Rev. Biochem. 74, 385-410
5. Johnson, Z., Proudfoot, A. E., and Handel, T. M. (2005) Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 16, 625-636
6. Hileman, R. E., Fromm, J. R., Weiler, J. M., and Linhardt, R. J. (1998) Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20, 156-167
7. Thompson, L. D., Pantoliano, M. W., and Springer, B. A. (1994) Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 33, 3831-3840
8. Wang, L., Fuster, M., Sriramarao, P., and Esko, J. D. (2005) Endothelial heparan sulfate deficiency impairs L-selectin-and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat. Immunol. 6, 902-910
9. Proudfoot, A. E., Handel, T. M., Johnson, Z., Lau, E. K., LiWang, P., Clark-Lewis, I., Borlat, F., Wells, T. N., and Kosco-Vilbois, M. H. (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. U.S.A. 100, 1885-1890
10. Severin, I. C., Gaudry, J. P., Johnson, Z., Kungl, A., Jansma, A., Gesslbauer, B., Mulloy, B., Power, C., Proudfoot, A. E., and Handel, T. (2010) Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans. J. Biol. Chem. 285, 17713-17724
11. Campanella, G. S., Grimm, J., Manice, L. A., Colvin, R. A., Medoff, B. D., Wojtkiewicz, G. R., Weissleder, R., and Luster, A. D. (2006) Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity. J. Immunol. 177, 6991-6998
12. Sarris, M., Masson, J. B., Maurin, D., Van der Aa, L. M., Boudinot, P., Lortat-Jacob, H., and Herbomel, P. (2012) Inflammatory chemokines direct and restrict leukocyte migration within live tissues as glycan-bound gradients. Curr. Biol. 22, 2375-2382
13. Massena, S., Christoffersson, G., Hjertström, E., Zcharia, E., Vlodavsky, I., Ausmees, N., Rolny, C., Li, J. P., and Phillipson, M. (2010) A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 116, 1924-1931
14. Bao, X., Moseman, E. A., Saito, H., Petryanik, B., Thiriot, A., Hatakeyama, S., Ito, Y., Kawashima, H., Yamaguchi, Y., Lowe, J. B., von Andrian, U. H., and Fukuda, M. (2010) Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes. Immunity 33, 817-829
15. Dyer, D. P., Thomson, J. M., Hermant, A., Jowitt, T. A., Handel, T. M., Proudfoot, A. E., Day, A. J., and Milner, C. M. (2014) TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8. J. Immunol. 192, 2177-2185
16. Kumar, A. V., Katakam, S. K., Urbanowitz, A. K., and Gotte, M. (2015) Heparan sulphate as a regulator of leukocyte recruitment in inflammation. Curr. Protein Pept. Sci. 16, 77-86
17. Salanga, C. L., and Handel, T. M. (2011) Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 317, 590-601
18. Middleton, J., Neil, S., Wintle, J., Clark-Lewis, I., Moore, H., Lam, C., Auer, M., Hub, E., and Rot, A. (1997) Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91, 385-395
19. Sadir, R., Imberty, A., Baleux, F., and Lortat-Jacob, H. (2004) Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J. Biol. Chem. 279, 43854-43860
20. Ellyard, J. I., Simson, L., Bezos, A., Johnston, K., Freeman, C., and Parish, C. R. (2007) Eotaxin selectively binds heparin: an interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. J. Biol. Chem. 282, 15238-15247
21. Weber, M., Hauschild, R., Schwarz, J., Moussion, C., de Vries, I, Legler, D. F., Luther, S. A., Bollenbach, T., and Sixt, M. (2013) Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 339, 328-332
22. Middleton, J., Patterson, A. M., Gardner, L., Schmutz, C., and Ashton, B. A. (2002) Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 100, 3853-3860
23. Kiefer, F., and Siekmann, A. F. (2011) The role of chemokines and their receptors in angiogenesis. Cell Mol. Life Sci. 68, 2811-2830
24. Vandercappellen, J., Van Damme, J., and Struyf, S. (2011) The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 22, 1-18
25. Keeley, E. C., Mehrad, B., and Strieter, R. M. (2011) Chemokines as mediators of tumor angiogenesis and neovascularization. Exp. Cell Res. 317, 685-690
26. Mantovani, A., Savino, B., Locati, M., Zammataro, L., Allavena, P., and Bonecchi, R. (2010) The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 21, 27-39
27. Mortier, A., Van Damme, J., and Proost, P. (2012) Overview of the mechanisms regulating chemokine activity and availability. Immunol. Lett. 145, 2-9
28. Mortier, A., Van Damme, J., and Proost, P. (2008) Regulation of chemokine activity by posttranslational modification. Pharmacol. Ther. 120, 197-217
29. Mortier, A., Gouwy, M., Van Damme, J., and Proost, P. (2011) Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp. Cell Res. 317, 642-654
30. Moelants, E. A., Mortier, A., Van Damme, J., and Proost, P. (2013) In vivo regulation of chemokine activity by post-translational modification. Immunol. Cell Biol. 91, 402-407
31. Nibbs, R. J., and Graham, G. J. (2013) Immune regulation by atypical chemokine receptors. Nat. Rev. Immunol. 13, 815-829
32. Schuh, J. M., Blease, K., Kunkel, S. L., and Hogaboam, C. M. (2003) Chemokines and cytokines: axis and allies in asthma and allergy. Cytokine Growth Factor Rev. 14, 503-510
33. Farber, J. M. (1993) HuMig: a new human member of the chemokine family of cytokines. Biochem. Biophys. Res. Commun. 192, 223-230
34. Groom, J. R., and Luster, A. D. (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207-215
35. Proost, P., Verpoest, S., Van de Borne, K., Schutyser, E., Struyf, S., Put, W., Ronsse, I., Grillet, B., Opdenakker, G., and Van Damme, J. (2004) Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-γ in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. J. Leukoc. Biol. 75, 777-784
36. Mortier, A., Berghmans, N., Ronsse, I., Grauwen, K., Stegen, S., Van Damme, J., and Proost, P. (2011) Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation. PLoS One 6, e23913
37. Van Raemdonck, K., Berghmans, N., Vanheule, V., Bugatti, A., Proost, P., Opdenakker, G., Presta, M., Van Damme, J., and Struyf, S. (2014) Angiostatic, tumor inflammatory and anti-tumor effects of CXCL447-70 and CXCL4L147-70 in an EGF-dependent breast cancer model. Oncotarget 5, 10916-10933
38. Loos, T., Mortier, A., and Proost, P. (2009) Chapter 1. Isolation, identification, and production of posttranslationally modified chemokines. Methods Enzymol. 461, 3-29
39. Moelants, E. A., Loozen, G., Mortier, A., Martens, E., Opdenakker, G., Mizgalska, D., Szmigielski, B., Potempa, J., Van Damme, J., Teughels, W., and Proost, P. (2014) Citrullination and proteolytic processing of chemokines by Porphyromonas gingivalis. Infect. Immun. 82, 2511-2519
40. Gerlza, T., Hecher, B., Jeremic, D., Fuchs, T., Gschwandtner, M., Falsone, A., Gesslbauer, B., and Kungl, A. J. (2014) A combinatorial approach to biophysically characterise chemokine-glycan binding affinities for drug development. Molecules 19, 10618-10634
41. 2-terminal region of CXCL5 by proteases or peptidylarginine deiminases (PAD) differently affects its biological activity. J. Biol. Chem. 285, 29750-29759
42. Gouwy, M., Struyf, S., Noppen, S., Schutyser, E., Springael, J. Y., Parmentier, M., Proost, P., and Van Damme, J. (2008) Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Mol. Pharmacol. 74, 485-495
43. Falsone, A., Wabitsch, V., Geretti, E., Potzinger, H., Gerlza, T., Robinson, J., Adage, T., Teixeira, M. M., and Kungl, A. J. (2013) Designing CXCL8-based decoy proteins with strong anti-inflammatory activity in vivo. Biosci. Rep. 33,
44. Clark-Lewis, I., Mattioli, I., Gong, J. H., and Loetscher, P. (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J. Biol. Chem. 278, 289-295
45. Struyf, S., Salogni, L., Burdick, M. D., Vandercappellen, J., Gouwy, M., Noppen, S., Proost, P., Opdenakker, G., Parmentier, M., Gerard, C., Sozzani, S., Strieter, R. M., and Van Damme, J. (2011) Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 117, 480-488
46. Kuschert, G. S., Hoogewerf, A. J., Proudfoot, A. E., Chung, C. W., Cooke, R. M., Hubbard, R. E., Wells, T. N., and Sanderson, P. N. (1998) Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry 37, 11193-11201
47. Nesmelova, I. V., Sham, Y., Dudek, A. Z., van Eijk, L. I., Wu, G., Slungaard, A., Mortari, F., Griffioen, A. W., and Mayo, K. H. (2005) Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J. Biol. Chem. 280, 4948-4958
48. Feldmann, M., Brennan, F. M., and Maini, R. N. (1996) Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-440
49. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241
50. Amaral, F. A., Costa, V. V., Tavares, L. D., Sachs, D., Coelho, F. M., Fagundes, C. T., Soriani, F. M., Silveira, T. N., Cunha, L. D., Zamboni, D. S., Quesniaux, V., Peres, R. S., Cunha, T. M., Cunha, F. Q., Ryffel, B., Souza, D. G., and Teixeira, M. M. (2012) NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis Rheum. 64, 474-484
51. Brandt, E., Petersen, F., and Flad, H. D. (1993) A novel molecular variant of the neutrophil-activating peptide NAP-2 with enhanced biological activity is truncated at the C-terminus: identification by antibodies with defined epitope specificity. Mol. Immunol. 30, 979-991
52. Ehlert, J. E., Petersen, F., Kubbutat, M. H., Gerdes, J., Flad, H. D., and Brandt, E. (1995) Limited and defined truncation at the C terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2): comparison of native and recombinant NAP-2 variants. J. Biol. Chem. 270, 6338-6344
53. Ehlert, J. E., Gerdes, J., Flad, H. D., and Brandt, E. (1998) Novel C-terminally truncated isoforms of the CXC chemokine β-thromboglobulin and their impact on neutrophil functions. J. Immunol. 161, 4975-4982
54. Krijgsveld, J., Zaat, S. A., Meeldijk, J., van Veelen, P. A., Fang, G., Poolman, B., Brandt, E., Ehlert, J. E., Kuijpers, A. J., Engbers, G. H., Feijen, J., and Dankert, J. (2000) Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J. Biol. Chem. 275, 20374-20381
55. Hensbergen, P. J., van der Raaij-Helmer, E. M., Dijkman, R., van der Schors, R. C., Werner-Felmayer, G., Boorsma, D. M., Scheper, R. J., Willemze, R., and Tensen, C. P. (2001) Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity. Eur. J. Biochem. 268, 4992-4999
56. Hensbergen, P. J., Verzijl, D., Balog, C. I., Dijkman, R., van der Schors, R. C., van der Raaij-Helmer EM, van der Plas, M. J., Leurs, R., Deelder, A. M., Smit, M. J., and Tensen, C. P. (2004) Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity. J. Biol. Chem. 279, 13402-13411
57. Denis, C., Deiteren, K., Mortier, A., Tounsi, A., Fransen, E., Proost, P., Renauld, J. C., and Lambeir, A. M. (2012) C-terminal clipping of chemokine CCL1/I-309 enhances CCR8-mediated intracellular calcium release and anti-apoptotic activity. PLoS One 7, e34199
58. Cox, J. H., Dean, R. A., Roberts, C. R., and Overall, C. M. (2008) Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. J. Biol. Chem. 283, 19389-19399
59. Liao, F., Rabin, R. L., Yannelli, J. R., Koniaris, L. G., Vanguri, P., and Farber, J. M. (1995) Human Mig chemokine: biochemical and functional characterization. J. Exp. Med. 182, 1301-1314
60. Van den Steen, P. E., Husson, S. J., Proost, P., Van Damme, J., and Opdenakker, G. (2003) Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem. Biophys. Res. Commun. 310, 889-896
61. Ali, S., Palmer, A. C., Banerjee, B., Fritchley, S. J., and Kirby, J. A. (2000) Examination of the function of RANTES, MIP-1α, and MIP-1β following interaction with heparin-like glycosaminoglycans. J. Biol. Chem. 275, 11721-11727
62. Loos, T., Dekeyzer, L., Struyf, S., Schutyser, E., Gijsbers, K., Gouwy, M., Fraeyman, A., Put, W., Ronsse, I., Grillet, B., Opdenakker, G., Van Damme, J., and Proost, P. (2006) TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab. Invest. 86, 902-916
63. Selvan, R. S., Ihrcke, N. S., and Platt, J. L. (1996) Heparan sulfate in immune responses. Ann. N.Y. Acad. Sci. 797, 127-139
64. Blackhall, F. H., Merry, C. L., Davies, E. J., and Jayson, G. C. (2001) Heparan sulfate proteoglycans and cancer. Br. J. Cancer 85, 1094-1098
65. Proost, P., Struyf, S., Loos, T., Gouwy, M., Schutyser, E., Conings, R., Ronsse, I., Parmentier, M., Grillet, B., Opdenakker, G., Balzarini, J., and Van Damme, J. (2006) Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res. Ther. 8, R107
66. Szekanecz, Z., Vegvari, A., Szabo, Z., and Koch, A. E. (2010) Chemokines and chemokine receptors in arthritis. Front. Biosci. (Schol. Ed.) 2, 153-167
67. Alcami, A., and Lira, S. A. (2010) Modulation of chemokine activity by viruses. Curr. Opin. Immunol. 22, 482-487
68. Allegretti, M., Cesta, M. C., Garin, A., and Proudfoot, A. E. (2012) Current status of chemokine receptor inhibitors in development. Immunol. Lett. 145, 68-78
69. Adage, T., Piccinini, A. M., Falsone, A., Trinker, M., Robinson, J., Gesslbauer, B., and Kungl, A. J. (2012) Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans. Br. J. Pharmacol. 167, 1195-1205
70. Liehn, E. A., Piccinini, A. M., Koenen, R. R., Soehnlein, O., Adage, T., Fatu, R., Curaj, A., Popescu, A., Zernecke, A., Kungl, A. J., and Weber, C. (2010) A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J. Am. Coll. Cardiol. 56, 1847-1857
71. Bedke, J., Nelson, P. J., Kiss, E., Muenchmeier, N., Rek, A., Behnes, C. L., Gretz, N., Kungl, A. J., and Gröne, H. J. (2010) A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage. Mol. Immunol. 47, 1047-1057
72. Piccinini, A. M., Knebl, K., Rek, A., Wildner, G., Diedrichs-Möhring, M., and Kungl, A. J. (2010) Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo. J. Biol. Chem. 285, 8782-8792